A. Akahane

发表

A novel non-xanthine adenosine A1 receptor antagonist.

K. Yoshida, T. Kusunoki, T. Shimazaki, 1995, European journal of pharmacology.

Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5 -a]pyridines.

Y. Tenda, K. Durkin, H. Itani, 2000, Bioorganic & medicinal chemistry.

Studies on the Syntheses of Sesquiterpene Lactones. I. Chemical Transformation of α-Santonin into Vulgarin, C4-Epivulgarin, and Arglanine

M. Ando, K. Takase, A. Akahane, 1978 .

Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability.

Y. Tenda, Y. Tomishima, F. Takamura, 2001, Chemical & pharmaceutical bulletin.

A reinvestigation of the reported synthesis of the spirobenzyl isoquinoline alkaloid, iso-ochotensine

Michael A. Gonzalez, J. Warmus, A. Meyers, 1997 .

Synthesis of the water-soluble adenosine A1 receptor antagonist FR166124 through a novel sequential Horner-Emmons / isomerization reaction

T. Kinoshita, I. Nakanishi, K. Durkin, 1999 .

Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.

T. Kinoshita, Y. Tenda, K. Durkin, 1999, Bioorganic & medicinal chemistry letters.

Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)- pyridazinebutanoic acid (FK 838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity.

T. Kinoshita, K. Yoshida, T. Kusunoki, 1999, Journal of medicinal chemistry.

Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist

Keizo Yoshida, T. Kusunoki, Y. Kita, 1996 .

Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors.

A. Iwashita, T. Yamaji, T. Mihara, 2004, Journal of pharmacological sciences.

The renal effects of FR-113453, a potent non-xanthine adenosine antagonist

Keizo Yoshida, T. Kusunoki, T. Shimazaki, 1990 .

Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition

A. Iwashita, Hiroko Yamamoto, T. Mihara, 2007, Journal of Pharmacology and Experimental Therapeutics.

Chiral formamidines. The mechanism of mono- and di-alkylation leading to chiral, non-racemic tetrahydroisoquinolines.

Michael A. Gonzalez, J. Warmus, A. Meyers, 1991 .

Renal effects of FK453: A potent non‐xanthine adenosine A1 receptor antagonist

Keizo Yoshida, T. Andoh, T. Kusunoki, 1995 .

Chiral formamidines. Asymmetric synthesis of 1,1-disubstituted tetrahydroisoquinolines.

Michael A. Gonzalez, J. Warmus, A. Meyers, 1991 .

Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists

S. Butcher, H. J. Olverman, R. Horton, 1997, British journal of pharmacology.